These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 22154360)

  • 1. Intravenous or oral vinorelbine plus capecitabine as first-line treatment in HER2- metastatic breast cancer: joint analysis of 2 consecutive prospective phase II trials.
    Strada MR; Palumbo R; Bernardo A; Riccardi A; Teragni C; Poggi G; Frascaroli M; Amatu A; Montagna B; Sottotetti F; Tagliaferri B; Bernardo G
    Clin Breast Cancer; 2012 Feb; 12(1):30-9. PubMed ID: 22154360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer.
    Chan A; Conte PF; Petruzelka L; Tubiana-Mathieu N; Ganju V; Llombart A; Espie M; Majois F; Gil MG; Vaissiere N; Villanova G
    Anticancer Res; 2013 Jun; 33(6):2657-64. PubMed ID: 23749924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
    Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. All-oral combination of vinorelbine and capecitabine as first-line treatment in HER2/Neu-negative metastatic breast cancer.
    Tawfik H; Rostom Y; Elghazaly H
    Cancer Chemother Pharmacol; 2013 Apr; 71(4):913-9. PubMed ID: 23344713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II trial of oral vinorelbine and capecitabine in anthracycline pretreated patients with metastatic breast cancer.
    Finek J; Holubec L; Svoboda T; Sefrhansova L; Pavlikova I; Votavova M; Sediva M; Filip S; Kozevnikova R; Kormunda S
    Anticancer Res; 2009 Feb; 29(2):667-70. PubMed ID: 19331218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer.
    Yoshimoto M; Takao S; Hirata M; Okamoto Y; Yamashita S; Kawaguchi Y; Takami M; Furusawa H; Morita S; Abe C; Sakamoto J
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):331-8. PubMed ID: 22526409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of capecitabine and vinorelbine as first-line chemotherapy for metastatic breast cancer patients.
    Ghosn M; Kattan J; Farhat F; Younes F; Gasmi J
    Anticancer Res; 2006; 26(3B):2451-6. PubMed ID: 16821631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer.
    Nolè F; Crivellari D; Mattioli R; Pinotti G; Foa P; Verri E; Fougeray R; Brandely M; Goldhirsch A
    Cancer Chemother Pharmacol; 2009 Sep; 64(4):673-80. PubMed ID: 19184601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer.
    Baselga J; Segalla JG; Roché H; Del Giglio A; Pinczowski H; Ciruelos EM; Filho SC; Gómez P; Van Eyll B; Bermejo B; Llombart A; Garicochea B; Durán MÁ; Hoff PM; Espié M; de Moraes AA; Ribeiro RA; Mathias C; Gil Gil M; Ojeda B; Morales J; Kwon Ro S; Li S; Costa F
    J Clin Oncol; 2012 May; 30(13):1484-91. PubMed ID: 22412143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vinorelbine and 5-fluorouracil bolus and/or continuous venous infusion plus levofolinic acid as second-line chemotherapy for metastatic breast cancer: an analysis of results in clinical practice of the Gruppo Oncologico Italia Meridionale (GOIM).
    Gebbia V; Caruso M; Borsellino N; Ajello R; Tirrito ML; Chiarenza M; Valenza R; Verderame F; Varvara F; Marrazzo A; Bajardi E; Ferrao F; Bordonaro R; Tralongo P
    Anticancer Res; 2006; 26(4B):3143-50. PubMed ID: 16886648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial.
    Tubiana-Mathieu N; Bougnoux P; Becquart D; Chan A; Conte PF; Majois F; Espie M; Morand M; Vaissiere N; Villanova G
    Br J Cancer; 2009 Jul; 101(2):232-7. PubMed ID: 19584872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase II trial of split, low-dose docetaxel and low-dose capecitabine: a tolerable and efficacious regimen in the first-line treatment of patients with HER2/neu-negative metastatic breast cancer.
    Silva O; Lopes G; Morgenzstern D; Lobo C; Doliny P; Santos E; Abdullah S; Gautam U; Reis I; Welsh C; Slingerland J; Hurley J; Gluck S
    Clin Breast Cancer; 2008 Apr; 8(2):162-7. PubMed ID: 18621613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.
    Gajria D; Gonzalez J; Feigin K; Patil S; Chen C; Theodoulou M; Drullinsky P; D'Andrea G; Lake D; Norton L; Hudis CA; Traina TA
    Breast Cancer Res Treat; 2012 Jan; 131(1):111-6. PubMed ID: 21898114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer.
    Blum JL; Dees EC; Chacko A; Doane L; Ethirajan S; Hopkins J; McMahon R; Merten S; Negron A; Neubauer M; Ilegbodu D; Boehm KA; Asmar L; O'Shaughnessy JA
    J Clin Oncol; 2006 Sep; 24(27):4384-90. PubMed ID: 16926223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.
    Martin M; Bonneterre J; Geyer CE; Ito Y; Ro J; Lang I; Kim SB; Germa C; Vermette J; Wang K; Wang K; Awada A
    Eur J Cancer; 2013 Dec; 49(18):3763-72. PubMed ID: 23953056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase II study of capecitabine and vinorelbine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes.
    Estévez LG; Batista N; Sánchez-Rovira P; Velasco A; Provencio M; León A; Dómine M; Cruz J; Rodríguez M
    Clin Breast Cancer; 2008 Apr; 8(2):149-54. PubMed ID: 18621611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A three-arm randomized phase II study of oral vinorelbine plus capecitabine versus oral vinorelbine and capecitabine in sequence versus docetaxel plus capecitabine in patients with metastatic breast cancer previously treated with anthracyclines.
    Campone M; Dobrovolskaya N; Tjulandin S; Chen SC; Fourie S; Mefti F; Konstantinova M; Lefresne F; Meheust N; Jassem J
    Breast J; 2013; 19(3):240-9. PubMed ID: 23528159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vinorelbine and capecitabine in anthracycline- and/or taxane-pretreated metastatic breast cancer: sequential or combinational?
    Zhang J; Gu SY; Gan Y; Wang ZH; Wang BY; Guo HY; Wang JL; Wang LP; Zhao XM; Hu XC
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):103-13. PubMed ID: 23053266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial.
    De Maio E; Pacilio C; Gravina A; Morabito A; Di Rella F; Labonia V; Landi G; Nuzzo F; Rossi E; Silvestro P; Botti G; Di Bonito M; Curcio MP; Formichelli F; La Vecchia F; Staiano M; Maurea N; D'Aiuto G; D'Aiuto M; Thomas R; Signoriello G; Perrone F; de Matteis A
    BMC Cancer; 2007 Mar; 7():50. PubMed ID: 17374151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective study of vinorelbine and capecitabine combination therapy in Chinese patients with metastatic breast cancer pretreated with anthracyclines and taxanes.
    Fan Y; Xu B; Yuan P; Wang J; Ma F; Li Q; Zhang P; Li Q; Cai R
    Chemotherapy; 2010; 56(4):340-7. PubMed ID: 20720418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.